Intravesicle Bacillus Calmette–Guérin (BCG) Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) in the Transplanted Patients Population: A Systematic Review of the World Literature

Abstract

Intravesicle Bacille Calmette-Guerin (BCG) is generally considered to be contraindicated in the immunosuppressed or compromised patients with bladder cancer (BC) because of ineffectiveness or partial toxicities. Therefore, there is little experience with BCG in individual with impaired immune system and this can be challenging to practicing urologists. We sought to review the current available evidence of utilizing intravesicle BCG for BC in patients with solid organ transplantation and commented on its current status.